alt alt
// The problem we are solving
Pain is the least
quantified condition
in the world we are changing that.
// The Problem
Pain is not a data driven disease
You are used to having data-driven outcomes in other disease states diabetes (CGM), heart health (mobile ECG and arrhythmia on our smart watches), and oncology (tumor biomarkers).
However, a simple Pain assessment tool is still used to investigate pain.
Patient Reported Outcome Measures | Celéri Health

This is a prehistoric method staggering innovation

// The Solution
The solution is Celéri Health. We have more than 15 indicators to assess a person’s condition.
Addressable indicators:
  • Pain Impact Score
  • Fatigue
  • Anxiety
  • Depression
  • Social Participation
Show allShow less
Fatigue 20.0 56.1 Anxiety 20.0 56.1 Depression 20.0 53.1 Physical Function 80.0 40.0 Pain Interference w/Activities
Pain Impact Score
Normal0
Patient data3
alt
Fatigue
Normal 20.0
Patient data59.0
alt
Anxiety
Normal 20.0
Patient data56.1
alt
Depression
Normal 20.0
Patient data53.1
alt
Social Participation
Normal 20.0
Patient data50.5
alt
Physical Function
Normal 80
Patient data40
alt
Sleep Disturbance
Normal 85%
Patient data 50%
alt
Pain Interference
Normal 20
Patient data47
alt
Heart Rate Variability (HRV)
Normal 20-200ms
Patient data114ms
alt
Morphine Milligram Equivalents (MMEs)
Normal <20MME/day
Patient data 90MME/day
alt
Electrocardiogram (ECG)
Normal 50-100 bpm
Patient data 82 bpm
alt
Oxygen Saturation (SPO2)
Normal 95-100%
Patient data98%
alt
Body Mass Index (BMI)
Normal 18-24
Patient data 27
alt
Electroencephalogram (EEG)
Normal >8 hz
Patient data 12 hz
alt
Medical Imaging
Normal 0
Patient data 2
alt
Biomarkers
Normal 239
Patient data568
alt
Opioid Risk
Normal >3
Patient data2
alt
Celéri Health - Real-world patient centric data Celéri Health - Real-world patient centric data
// How it works
Measuring
what matters

If you can’t measure it, you can’t improve it. Our technology allows medical professionals to treat each patient encounter like a study visit.

Through our Multichannel High-Resolution Data Capture, we collect patient-reported outcomes and translate them into a common measurement language. We are marrying the subjective (PROs) with the objective (HRV, EEG, and urine biomarkers) to make pain a data-driven disease.

Come talk to us about the billion dollar opportunity to make pain a data driven disease.

 

// Key indicators in the industry
Pain by the numbers
600+
users
75+
practices across the US
6.5M
data points
60k+
patients
400k+
reports
Total cost of chronic diseases in the US in 2020
Total Cost
$3.7 trillion
  • Cardiovascular conditions $1,461 B
  • Arthritis and back pain $843 B
  • Diabetes $526 B
  • Cancers $281 B
  • Alzheimer’s $268 B
  • Other $267 B
// Progress points
Milestones achieved
2018
Oct
First Platform
Use
2019
Feb
Soft Launch,
1st Physician
Subscriber
Apr
1st Clinical Study
Signed (PROSPER)
Jul
PROSPER Study
Commences
Celéri Health - Opioid Risk Assessment Tool | Promis measures Celéri Health - Opioid Risk Assessment Tool | Promis measures
Dec
2nd Clinical Study
Signed (CornerLoc)
2020
Feb
Universal EMR
Integration
May
Signed
Medtronic
Study
Dec
>40k Patients
>200k Assessments
2021
Feb
Medtronic
Study
Commences
March
PainTEQ
Study
Commences
Apr
Aurora
Study
Commences
July
Interaxon
Partnership
Established
Aug
Ethos
Study
Commences
2022
Jan
$2M Angel
Round
Closed
waves waves
// Why our clients choose us
Value
proposition
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Patients
Right therapy at the right time
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Device / Drug Cos.
Real world evidence for label claims, label expansion, and reimbursement, as well as sales tools
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Providers
Best therapy, performance measurement, payer negotiations, and reimbursement
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Payers
Better understanding of outcomes and ability to pay for performance/outcomes
dots
// 75+ partners
Companies already using our data
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Have questions? Ask us anything.
// How data is used
Case
studies
01
Corroborating Functional Biomarkers of Pain with Ethos Labs
Ethos Labs Foundation Pain Index (FPI) has developed a composite score comprised of a panel of eleven functional pain biomarkers, which is based on the abnormal biochemistry...
Read more
Corroborating Functional Biomarkers of Pain with Ethos Labs

Ethos Labs Foundation Pain Index (FPI) has developed a composite score comprised of a panel of eleven functional pain biomarkers, which is based on the abnormal biochemistry described in a population study of over 17,000 patients on opioids for chronic pain. The Celeri Health Real World Outcomes platform was used to cross-validate these results with PROs to better understand the daily lives of individuals with chronic pain in the context of their biomarker profiles. The result of the analysis detailing the corroboration between the FPI and PROMIS-29 in real-world patients noted significant associations with multiple domains, including physical function, pain impact score, fatigue, pain interference, and depression. This validates the utility of the FPI for identifying the composite chronic pain state. Continued research is underway to calibrate this approach so as to define next step in clinical decision making.

dots
02
Identify Objective Measures of Pain with Muse
Celeri Health is being used to study objective measures for changes in pain sensitivity. Due to limited tools to quantify pain clinically, clinicians rely on patient reported scales to determine pain…
Read more
Identify Objective Measures of Pain with Muse

Celéri Health is being used to study objective measures for changes in pain sensitivity. Due to limited tools to objectively quantify pain clinically, clinicians rely on patient reported scales to determine pain treatment options (e.g.,opioid dosage is typically to the patient’s estimate of pain). Without an objective test of pain sensitivity, a kind of “blood pressure” equivalent to pain, treatment decisions rely on patient’s claims of pain, which may be based on the patient’s desire for treatments due to addiction or anxiety about pain that they experience as intolerable. Patient’s know that if they report more pain, it is likely that their physician will prescribe more pain medication. For this reason, objective tests for pain sensitivity are needed to assess patient’s complaints with precision.

The Celéri Health platform is being used in conjunction with the Muse S (choosemuse.com) biofeedback training device to assess impact on quality of life using PROs, bio-signals (EEG, HRV, Cerebral SpO2), and pain tolerance and sensitivity using a cold pressor test.  This multichannel data capture study will allow us to objectively correlate bio-signals of pain with the patient’s mood, sleep, and function is currently underway. Further information can be found here at Clinicaltrials.gov.

03
PROMIS-29 is a Compass for Care
As a patient living with chronic pain, it was frustratingly inadequate to communicate the challenges we face in everyday life on a 0-10 scale. As a Celéri Health patient, my clinician starts each visit by measuring what matters in pain care...
Read more
PROMIS-29 is a Compass for Care

As a patient living with chronic pain, it was frustratingly inadequate to communicate the challenges we face in everyday life on a 0-10 scale. As a Celéri Health patient, my clinician starts each visit by measuring what matters in pain care. Each chronic pain experience is multidimensionally assessed with the PROMIS-29 profile to quantify individualized impacts on mood, sleep, function, social participation, and pain interference with daily activities. Reviewing these longitudinal assessments at the beginning of each visit serves as a compass for care, and helps my medical team focus on meaningful goals for care.

At Celéri Health we understand that not all patients are the same. Our co-founders Dr. Michael Fishman was recently interviewed alongside one of his patients. Listening to the chronic pain journey and impact of treatment on quality of life is a driving force behind what we do at Celéri Health.

PROMIS® Adult Self-Reported Health Outcomes
Physical Health Mental Health Social Health
PROMIS

Profile

Domains

Fatigue

Pain Intensity

Pain Interference

Physical Function

Sleep Disturbance

Anxiety

Depression

Ability to Participate in Social Roles & Activities
PROMIS

Additional

Domains

Dyspnea

Gastrointerstinal

Symptoms

Itch

Pain Behavior

Pain Quality

Pain Function

Sexual Function

Sleep-related Impairment

Alcohol

Anger

Congnitive Function

Life Satisfaction

Meaning & Purpose

Positive Affect

Psychosocial Illness Impact

Self-efficacy for Managing Chronic Conditions

Smoking

Substance Use

Companionship

Satisfaction with Social Roles & Activities

Social Isolation

Social Support

Source: https://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis

// Our network
Partners
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Celéri Health - Opioid Risk Assessment Tool | Promis measures
dots
// Thought leadership
Celeri Health Advisors
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Tim Deer, MD
Dr. Deer is the world leader in research, product development, and education in the practice of Interventional Spine and Pain treatment. He is the President and CEO of The Spine and Nerve Centers of the Virginias. He is also a Clinical Professor of Anesthesiology at the West Virginia University School of Medicine.
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Tim Deer
Advisor

Dr. Deer is the world leader in research, product development, and education in the practice of Interventional Spine and Pain treatment. He is the President and CEO of The Spine and Nerve Centers of the Virginias. He is also a Clinical Professor of Anesthesiology at the West Virginia University School of Medicine.

Tim has been a leader in the field of interventional techniques and neuromodulation for more than two decades.  His rich research career has included many pivotal studies to achieve FDA approval and many “first in man” approved devices. Dr. Deer has provided cadaver based training to over 2000 physicians in novel methods of pain relief without the need for opioids. His work has led to more then 100 peer reviewed publications, several book chapters and full text books. Dr. Deer’s publications have included guidance for the proper use of Neuromodulation to improve safety and efficacy. His text books have included comprehensive guidance on pain, implantable devices and his current project Deer’s Illustrated Guide to the Treatment of Pain has become a text for many of those doing implantable therapies. His new book, Deer’s Treatment of Pain is inclusive of other interventional options as well as the physiology and noninvasive treatment of pain.

Tim has held many national and international society positions including his current roles as the Chairman of the American Society of Pain and Neuroscience Past President of the International Neuromodulation Society (INS) and President Emeritus of the West Virginia Society of Interventional Pain Physicians (WVSIPP). He is the past Chairman of the American Society of Anesthesiologist Committee of Pain Medicine and a Member of the West Virginia Controlled Substance Monitoring Program and has been involved in the peer review process to improve the quality of research in the international arena.

In addition to his many endeavors in Medicine, Tim is an avid ultrarunner completing several 100 mile races, the world’s hardest race, The Badwater 135 and the Florida Keys 50 mile run where he won the male overall championship in 2017. He also has completed over 20 full distance Ironman races, including 6 trips to compete in the Ironman World Championships in Kona, Hawaii.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Steven Falowski, MD
Dr. Falowski is Director, Functional Neurosurgery St Luke’s University Health Network. He is a board certified Functional Neurosurgeon and with a practice specializing in Neuromodulation.
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Steven Falowski, MD
Advisor

Dr. Falowski is Director, Functional Neurosurgery St Luke’s University Health Network. He is a board certified Functional Neurosurgeon and with a practice specializing in Neuromodulation.

Steve is Senior Advisor and past Secretary of North American Neuromodulation Society, he is a Board Member International Neuromodulation Society, Board Member Pacific Pain and Spine Society and Secretary and Treasurer Executive Pain Committee. Steve is on the Faculty of the Congress of Neurological Surgeons and of the American Association Neurological Surgeons, he is Executive Officer of the Board, American Society Pain and Neuroscience.

 

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Michael Hanes, MD
Dr. Hanes is double board-certified in Anesthesiology and Pain Medicine. He is one of the owners of and Chief Medical Officer at Jax Spine & Pain Centers in Jacksonville, FL.
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Michael Hanes, MD
Advisor

Dr. Hanes is double board-certified in Anesthesiology and Pain Medicine. He is one of the owners of and Chief Medical Officer at Jax Spine & Pain Centers in Jacksonville, FL.

Michael is a published educator and national speaker in the field of interventional pain medicine and is a strong proponent of providing safe, effective and empathetic care options to patients experiencing chronic or acute pain. He started the Centurion Spine Research Institute and is a principal investigator on several research projects focused on minimally invasive spine surgery and neurostimulation. He is a University of Michigan football fan and spends his free time at the gym. He and his wife are members of Our Lady Star of the Sea Catholic Church as well as advocates for the hearing-impaired community. They are dedicated to helping spread awareness of hearing impairment and improving education to those affected by hearing loss.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jay Shah, MD
Jay M. Shah MD, FAAPMR is a double-board certified physician specializing in Interventional Pain Medicine and Physical Medicine and Rehabilitation (PM&R/Physiatry), and is the Founder, Chief Physician Executive, and Medical Director of the SamWell Institute for Pain Management in central and northern New Jersey.
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jay Shah, MD, FAAPMR
Advisor

Dr. Shah is a double-board certified physician specializing in Interventional Pain Medicine and Physical Medicine and Rehabilitation (PM&R/Physiatry), and is the Founder, Chief Physician Executive, and Medical Director of the SamWell Institute for Pain Management in central and northern New Jersey.

Jay completed his training in Interventional Pain Medicine at the prestigious ACGME accredited Weill-Cornell Tri-Institutional Pain Fellowship in NY. There, he trained at three of the nation’s top hospitals: Memorial Sloan Kettering Cancer Center, The Hospital for Special Surgery, and New York Presbyterian Hospital/Weill-Cornell Medical College.

Jay is widely considered a rising star and young physician leader within the field of Pain Medicine. His truly patient-centered, multidisciplinary, and evidence-based approach aims to provide personalized care to each individual patient and their specific needs. Through novel, non-surgical, and minimally invasive interventional techniques, Dr. Shah utilizes the latest technologies to help restore and maximize function as well as overall wellness of patients with chronic musculoskeletal pain related to degenerative conditions and sports-related injuries. This includes non-surgical orthopedic treatments for low back, neck, knee, shoulder, and hip pain as well as pain after neck or back surgeries.

Jay is a strong advocate for evidence-based clinical outcomes and strongly believes in the power of real world clinical outcomes through the Celeri platform.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Steven Popielarski, PhD
Dr. Popielarski develops, launches and grows disruptive healthcare solutions. He is currently President and CEO of Thermaquil, Inc. which is developing the world’s first noninvasive and minimally invasive drug-free nerve block devices.
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Steven Popielarski, PhD
Advisor

Dr. Popielarski develops, launches and grows disruptive healthcare solutions. He is currently President and CEO of Thermaquil, Inc. which is developing the world’s first noninvasive and minimally invasive drug-free nerve block devices.

Before founding Thermaquil, Steve got back to his entrepreneurial roots by starting SPHM Enterprises to provide startups and high-growth companies with strategy consulting, marketing training, commercial and operational leadership. This exposure to a wide swath of startups represented a significant change from global marketing with Fortune 50/500 companies where he managed a $2B portfolio of consumer-use medical devices, developed and launched a SaaS business model to drive innovative device adoption, and separately oversaw the launch of a noninvasive neuromodulation system for overactive bladder.

Earlier in his career, Steve was in business development and strategic marketing at molecular diagnostics startup GeneOhm Sciences, which pursued parallel IPO and acquisition paths leading to acquisition for $250M with $5M prior year revenue. Steve has a PhD in Chemical Engineering from Caltech in Pasadena, where his thesis and frequently cited papers uncovered critical parameters for nonviral gene therapy vectors to specifically target hepatocytes in the liver.  His BS is in Materials Science and Engineering from Rensselaer Polytechnic Institute in Troy, NY.

 

Wasim Q. Malik, PhD
As the Managing Partner, Wasim oversees the overall strategy, investments and partnerships at Iaso Ventures.
Read more
Wasim Q. Malik, PhD
Advisor

As the Managing Partner, Wasim oversees the overall strategy, investments and partnerships at Iaso Ventures.

He previously served as the first Chief Digital Strategist at Roivant Sciences, a global biopharma company ($7.3B IPO). There he led digital health investments, strategy and partnerships to help accelerate drug development and commercialization across 15+ therapeutic areas, and contributed to incubation and early growth of various portfolio companies.

As part of his work in the healthcare provider industry, Wasim has served on the faculty at Massachusetts General Hospital, the flagship teaching hospital of Harvard Medical School, for over a decade. Affiliated with the MGH Department of Psychiatry and the Clinical Trials Network and Institute, he built a research program on tech-enabled clinical research in neurology, psychiatry and anesthesiology, with a focus on neurodegenerative and movement disorder biomarkers, and brain-computer interfaces.

He serves on the Steering Committee of the NIH EPPIC-Netand IEEE Brain Initiative, the grant review panels for NSF and NASA TRISH, and the national scientific research councils of 6 countries. His work has been featured in multiple media outlets including the Wall Street Journal, New York Times, BBC World, and others.

// Key people
The team
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jon Brilliant
CEO
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jon Brilliant
CEO

Jon was a co-founder and the CFO of Big Foot Biomedical, a Silicon Valley based company focused on reducing the burden of living with insulin requiring diabetes and to maximize the leverage of health care providers through data, connectivity, automation and artificial intelligence. Prior to Big Foot, Jon was a founding board member and CFO of Well Doc, the pioneer in digital health founded in 2005 – first mobile app cleared by FDA, prescribed by physicians and reimbursed by payers.  Over the years, Jon has been a board member and/or strategic advisor to one of the leading venture funds in digital health and many digital health companies ranging from cancer management, mindfulness, schedule optimization, mental health and substance use disorder.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Michael Fishman, MD, MBA
Co-Founder
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Michael Fishman, MD, MBA
Co-Founder

Dr. Fishman is a practicing pain specialist in the Philadelphia area with a diverse clinical practice that includes innovation, clinical research, and the evidence-based treatment of painful conditions. At Celéri Health, Dr. Fishman is committed to redefining the outcomes metrics we use to measure response to pain care and neuromodulation through the clinical development of the Real World Outcomes platform. Dr. Fishman received his undergraduate degree at Franklin & Marshall College, his medical degree at Jefferson Medical College and a Masters of Business Administration at Drexel University’s LeBow College of Business. He also completed his internship at Lankenau Hospital, residency in anesthesiology at Yale University, and pain medicine fellowship at Stanford University. He is on the Board of Directors of the North American Neuromodulation Society and is a key opinion leader in the field of neuromodulation and interventional pain care, frequently publishing and presenting his work on national and international podiums.

 

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jason Pope, MD, DABPM, FIPP
Co-Founder
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jason Pope, MD, DABPM, FIPP
Co-Founder

Dr Pope is the President & CEO of Evolve Restorative Center in Northern California. He is the President of the California Society of Interventional Pain Physicians and serves the North American Neuromodulation Society (NANS) as an ex-officio director at large for the International Neuromodulation Society, is the co-chair for the CME committee, the co-chair for the pre-conference training workshop in the biennial meeting in Sydney, Australia, and the co-chair for the Young Neuromodulation Committee.  He also is the co-founder of the Special Interest Group in Neuromodulation for the American Society of Regional Anesthesia (ASRA). Dr Pope has published over 100 peer-reviewed articles while working with medical device start up companies and established industry partners to provide strategic planning and execution for patient-centric adoption and supportive patient outcomes.

Celéri Health | Terms of Service | Patient-reported Outcomes
David Tannenbaum
Co-Founder & Chief Technology Officer
Read more
Celéri Health | Terms of Service | Patient-reported Outcomes
David Tannenbaum
Co-Founder & Chief Technology Officer

David has more than a decade of experience leading and managing successful technology companies. David was the Founder & CTO of Loan Ecosystem Online. Prior to founding Loan Ecosystem Online, David was CTO of PulsePoint and BlueCava which were acquired by WebMD and Qualia respectively. David was the Chief Technology Officer of LiftDNA, a leading SSP (sell-side platform), before it was acquired by OpenX in February 2012. Prior to LiftDNA, David served as the Chief Architect of mOcean, the industry leading solution to mobile ad serving which was acquired by Pubmatic.

David began his career as a Systems Engineer at Sun Microsystems and was later recruited by TimeSys as one of its first employees to work on Real Time Linux and Java. David graduated with a degree in Computer Science Engineering from the University of Pennsylvania.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Chris Mellor, MBA
VP of Business Development
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Chris Mellor, MBA
VP of Business Development

Chris graduated with a BS in Finance & Operations Management from the University of Delaware and subsequently spent 6 years working on JP Morgan’s US Treasury Desk as a trading assistant. Chris traded NYC for Chapel Hill where he received is MBA from University of North Carolina with a concentration in Entrepreneurship. Upon graduation and prior to joining Celeri Health, Chris was drawn to the world of entrepreneurship and found himself working for a digital start up based in Cape Town, South Africa helping develop market entry strategy and leading US Operations.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Carol Cottone
Chief People Officer
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Carol Cottone
Chief People Officer

Carol was a founding partner and Executive Vice President of The Higgins Group, one of the top executive search firms in the life science industry. Over her 20 year career in executive search, Carol gained a reputation for her insights, integrity and an ability to build and retain strong teams. She successfully coached many executives on how to bring out the best in themselves and their teams.  Previously, Carol was a co-founder & commercial officer in a software start up based in Philadelphia. Carol earned a Bachelor of Science degree with Honors from University of Maryland.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jean Myers
Director, Clinical Operations
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Jean Myers
Director, Clinical Operations

Jean is a Clinical Research Professional with over 20 years experience leading global clinical studies in both the CRO and pharmaceutical industries.   Her clinical trial management expertise spans Phase I-IV studies across multiple therapeutic areas. Jean is committed to leveraging Patient Reported Outcomes and Real World Data from Electronic Health Records to enhance a product’s value story and ensure smart decisions are made for the treatment of pain through analysis of real-world evidence and the patient experience.

Celéri Health - Opioid Risk Assessment Tool | Promis measures
Lindsay Kate Wanner
Senior Clinical Research Associate
Read more
Celéri Health - Opioid Risk Assessment Tool | Promis measures
Lindsay Kate Wanner
Senior Clinical Research Associate

Lindsay Kate graduated from Franklin and Marshall with a BA in Biological Foundations of Behavior, Neuroscience. Prior to joining Celéri Health she spent two years working as a Clinical Research Coordinator and medical assistant at a pain management practice in the Philadelphia area. Lindsay Kate has an interest in Neuromodulation and the role Real World Outcomes plays in personalizing Neuromodulation treatments.

Lori Mingione
Operations Manager
Read more
Lori Mingione
Operations Manager

Lori has over 20 years of professional experience in business operations across several different industries. Throughout her career she has focused on increasing operational efficiency by streamlining business processes and implementing strategic initiatives. Lori has always had a passion for healthcare and is dedicated to the mission of Celéri Health.

Ask us
anything
Schedule demo
Please schedule a time that works for you and we will connect with you to provide a demo.
Contact
Let us know how to reach you and we will be in touch within 24 hours.
Ask us anything
Talk to us
Let us know how to reach you and we will be in touch within 24 hours
Apply now
File type: doc, docx, pdf, xls, xlsx. File size: 10Mb.
sent
Request sent
"Thank you for your inquiry, we will be in touch within 24 hours."
Done